Navitoclax and UBX0101 are potential senolytic agents for alleviating osteoarthritis (OA), and the clinical trial for UBX0101 (NCT03513016) has been completed.

Authors

• Person: Not available Organization: Nature
  Cellular rejuvenation: molecular mechanisms and potential ... - Nature

Sources

• Cellular rejuvenation: molecular mechanisms and potential ... - Nature www.nature.com Nature via serper

Referenced by nodes (1)

• osteoarthritis concept